0001181431-13-063433.txt : 20131218
0001181431-13-063433.hdr.sgml : 20131218
20131218180959
ACCESSION NUMBER: 0001181431-13-063433
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20131217
FILED AS OF DATE: 20131218
DATE AS OF CHANGE: 20131218
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: TETRALOGIC PHARMACEUTICALS CORP
CENTRAL INDEX KEY: 0001361248
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 343 PHOENIXVILLE PIKE
CITY: MALVERN
STATE: PA
ZIP: 19355
BUSINESS PHONE: 610-889-9900
MAIL ADDRESS:
STREET 1: 343 PHOENIXVILLE PIKE
CITY: MALVERN
STATE: PA
ZIP: 19355
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Amgen Ventures LLC
CENTRAL INDEX KEY: 0001576997
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36208
FILM NUMBER: 131286370
BUSINESS ADDRESS:
STREET 1: ONE AMGEN CENTER DRIVE
CITY: THOUSAND OAKS
STATE: CA
ZIP: 91320-1799
BUSINESS PHONE: 805-447-1000
MAIL ADDRESS:
STREET 1: ONE AMGEN CENTER DRIVE
CITY: THOUSAND OAKS
STATE: CA
ZIP: 91320-1799
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: AMGEN INC
CENTRAL INDEX KEY: 0000318154
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36208
FILM NUMBER: 131286371
BUSINESS ADDRESS:
STREET 1: ONE AMGEN CENTER DRIVE
CITY: THOUSAND OAKS
STATE: CA
ZIP: 91320
BUSINESS PHONE: (805)447-1000
MAIL ADDRESS:
STREET 1: ONE AMGEN CENTER DRIVE
CITY: THOUSAND OAKS
STATE: CA
ZIP: 91320
FORMER NAME:
FORMER CONFORMED NAME: AMGEN
DATE OF NAME CHANGE: 19870305
4
1
rrd395732.xml
FORM 4
X0306
4
2013-12-17
1
0001361248
TETRALOGIC PHARMACEUTICALS CORP
TLOG
0000318154
AMGEN INC
ONE AMGEN CENTER DRIVE
THOUSAND OAKS
CA
91320
0
0
1
0
0001576997
Amgen Ventures LLC
ONE AMGEN CENTER DRIVE
THOUSAND OAKS
CA
91320
0
0
1
0
Common Stock
2013-12-17
4
C
0
448767
0
A
448767
D
Common Stock
2013-12-17
4
C
0
268116
0
A
268116
I
By Ventures
Common Stock
2013-12-17
4
X
0
1141
6.4022
A
269257
I
By Ventures
Common Stock
2013-12-17
4
P
0
272142
7.00
A
541399
I
By Ventures
Convertible Notes
7.00
2013-12-17
4
C
0
3000000
0
D
Common Stock
448767
0
D
Series B Convertible Preferred Stock
2013-12-17
4
C
0
108932
0
D
Common Stock
108932
0
I
By Ventures
Series C Convertible Preferred Stock
2013-12-17
4
C
0
117361
0
D
Common Stock
117361
0
I
By Ventures
Convertible Notes
7.00
2013-12-17
4
C
0
279103
0
D
Common Stock
41823
0
I
By Ventures
Series C Convertible Preferred Stock Warrants (Right To Buy)
6.4022
2013-12-17
4
X
0
13355
0
D
Common Stock
13355
0
I
By Ventures
Owned directly by Amgen Ventures LLC ("Ventures"), a wholly-owned subsidiary of Amgen Inc. ("Amgen"). Amgen may be deemed to beneficially own securities held by Ventures, but disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein.
As more fully described in the Issuer's Registration Statement on Form S-1 (Registration No. 333-191811) (the "Registration Statement"), in connection with the Issuer's initial public offering (the "Offering"), upon the closing of the Offering, (i) each outstanding share of the Issuer's preferred stock was converted on a one-for-one basis into the Issuer's common stock, (ii) certain warrants for the right to purchase Series C Convertible Preferred Stock were exercised on a one-for-one basis at the exercise price reported herein and converted into common stock of the Issuer on a one-for-one basis, and (iii) the Issuer's common stock was issued upon conversion of the convertible notes by dividing the face value of such notes plus accrued interest due on such notes by the initial public offering price of the Issuer's common stock.
In accordance with the terms of the Warrant to Purchase Equity Securities, the warrant was net exercised and based on a fair market value of $7.00 per share, a net of 1,141 shares were acquired by Ventures.
/s/ David J. Scott Senior Vice President, General Counsel and Secretary on behalf of Amgen Ventures LLC and Amgen Inc.
2013-12-17